Dissolvable Tobacco Products

Tobacco Products Scientific Advisory Committee Meeting
January 20, 2012

Sarah E. Evans, PhD
Office of Science
Center for Tobacco Products, FDA
DISCLAIMER: The information in these materials is not a formal dissemination of information by FDA and does not represent agency position or policy. The information is being provided to TPSAC to aid the committee in its evaluation of the issues and questions referred to the committee.
Today’s Meeting

• Presentations on youth perception of dissolvable tobacco products
• Committee Discussion
The Report on the Nature and Impact of the Use of Dissolvable Tobacco Products on the Public Health: What to Expect
Future TPSAC Meetings

• Tentatively scheduled for March 1-2, 2012
• Will be announced via Federal Register Notice
The nature and impact of the use of dissolvable tobacco products on the public health

907(f) DISSOLVABLE TOBACCO PRODUCTS.—

• (1) REFERRAL; CONSIDERATIONS.—The Secretary shall refer to the Tobacco Products Scientific Advisory Committee for report and recommendation, under section 917(c)(4), the issue of the nature and impact of the use of dissolvable tobacco products on the public health, including such use among children. In its review, the Tobacco Products Scientific Advisory Committee shall address the considerations listed in subsection (a)(3)(B)(i).

• (2) REPORT AND RECOMMENDATION.—Not later than 2 years after its establishment, the Tobacco Product Scientific Advisory Committee shall submit to the Secretary the report and recommendations required pursuant to paragraph (1).
Plans for Developing The Report

• We anticipate holding one meeting on this topic before March 23, 2012.
• Detailed minutes and *verbatim* transcripts will be prepared for each meeting.
• The compiled minutes, transcripts, and other materials from the series of meetings will be included in the committee report.
Final Report

The final report from TPSAC will be made available to the public on FDA’s Web site once it has been reviewed for redaction of any commercial confidential or trade secret information.
FDA Actions

- Once the report from TPSAC is received, FDA will consider the report and recommendations of the Committee, as well as other scientific evidence concerning dissolvable tobacco products and make a determination about what action(s), if any, are warranted.
- There is no required deadline or timeline for FDA to make such a determination.
- Any sale/distribution restrictions (Section 906(d)) or product standards (Section 907) would be implemented through notice-and-comment rulemaking.
Clarifying Questions?